Lucid Diagnostics (NASDAQ:LUCD) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $8.25. They now have a "buy" rating on the stock.
Lucid Diagnostics (NASDAQ:LUCD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% [Yahoo! Finance]
Lucid Diagnostics (NASDAQ:LUCD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.